uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
11.32
+0.42 (3.85%)
Mar 4, 2025, 3:57 PM EST - Market open
uniQure Employees
uniQure had 480 employees as of December 31, 2023. The number of employees decreased by 21 or -4.19% compared to the previous year.
Employees
480
Change (1Y)
-21
Growth (1Y)
-4.19%
Revenue / Employee
$56,498
Profits / Employee
-$499,075
Market Cap
612.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
QURE News
- 5 days ago - uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 6 days ago - uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
- 12 days ago - uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
- 25 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 25 days ago - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - PRNewsWire
- 4 weeks ago - uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 4 weeks ago - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewsWire
- 7 weeks ago - uniQure Announces Pricing of its Public Offering - GlobeNewsWire